These results indicate that UBE2L6 is prominently upregulated during leukemic cell differentiation rather than solely on ATRA treatment and that this effect is not restricted to APL cells carrying the PML‐RARα fusion oncoprotein. This evidence concerns the gene UBE2L6 and acute promyelocytic leukemia.